PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 14, 2026Journal of Clinical Oncology0 citations

Combining the albumin-bilirubin (ALBI) score and ECOG performance status for enhanced prognostication in advanced biliary tract cancer treated with durvalumab-based immunochemotherapy.

View Full Paper
CLChi-Chen LanWHWen-kuan HuangCWChunfeng Wu

Key Points

  • To evaluate the prognostic value of combining the ALBI score with ECOG performance status in advanced biliary tract cancer patients.
  • Analyzed advanced biliary tract cancer patients treated with durvalumab-based immunochemotherapy at three Taiwanese institutions.
  • Used Kaplan–Meier and Cox regression analyses to estimate survival outcomes.
  • Stratified patients into ALBI tertiles and assessed tumor response and adverse events using standard criteria.
  • Median overall survival was 13.8 months, and median progression-free survival was 5.1 months.
  • Combining ALBI with ECOG performance status yielded higher predictive accuracy for survival than either score alone.
  • Higher ALBI scores indicated poorer tumor response rates and increased toxicities.

Abstract

485 Background: The Eastern Cooperative Oncology Group performance status (ECOG PS) is fundamental for prognostication in advanced biliary tract cancer (BTC). The albumin-bilirubin (ALBI) score objectively reflects hepatic reserve; however, its value in combination with ECOG PS for patients treated with durvalumab plus gemcitabine-cisplatin (GCD) remains unclear. Methods: We analyzed consecutive patients with advanced BTC treated with first-line GCD at three Taiwanese institutions between August 2021 and March 2025. Patients were stratified into cohort-specific ALBI tertiles (Q1–Q3). Survival outcomes were estimated using Kaplan–Meier and Cox regression analyses. Tumor response and adverse events were assessed using RECIST v1.1 and CTCAE v5.0, respectively. Predictive accuracy for 6- and 12-month overall survival (OS) was compared among ECOG PS, ALBI, and their combination using time-dependent area under the receiver operating characteristic curves (AUC) and the Akaike information criterion (AIC). Results: Among 172 patients, the median OS was 13.8 months and progression-free survival (PFS) was 5.1 months. OS decreased progressively from ALBI Q1 to Q3 (24.0, 14.4, and 5.9 months; p < 0.001). In multivariate analysis, ALBI Q3 (vs. Q1) remained independently associated with poorer OS (adjusted hazard ratio HR 2.16, p = 0.016). ALBI correlated with ECOG PS (p = 0.004), but each maintained independent prognostic value. Combined ALBI + ECOG yielded higher AUCs (0.750 at 6 months; 0.683 at 12 months) and lower AICs than either model alone. The median OS ranged from 24.0 months in patients with ECOG 0–1 and ALBI Q1 to 2.4 months in those with ECOG 2–3 and ALBI Q3. Higher ALBI scores predicted lower response rates and increased toxicities ≥ grade 3. Conclusions: Baseline ALBI score independently predicted survival, tumor response, and toxicity risk in patients with advanced BTC treated with GCD. Combining ALBI with ECOG PS improves prognostic discrimination and may guide treatment and stratification in advanced BTC.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lan et al. (2026) studied this question.

synapsesocial.com/papers/6966e73f13bf7a6f02bffd9dhttps://doi.org/10.1200/jco.2026.44.2_suppl.485
Ask AI
Helpful
Bookmark
Share
View Full Paper